Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma By Ogkologos - June 1, 2026 200 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HERIZON-GEA-01 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR FDA Approves Pembrolizumab for Advanced Oesophageal or Gastro-Oesophageal Carcinoma March 30, 2021 “Mi corazón siempre dolerá”: Cómo honro a mi mejor amiga de... April 26, 2022 A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in... July 11, 2024 Routes to a healthier shopping journey – how your supermarket environment... April 19, 2023 Load more HOT NEWS Young Mom Gives Birth To Healthy Baby Boy In The Midst... Embracing Bravery When You Have a Genetic Cancer Disease Magnetic Fish-Shaped Microbots Deliver Chemotherapy to Exactly Where It’s Needed Penn State Researchers Working on Amazon Alexa Skill for Metastatic Breast...
